•	Application No.	Applicant(s)
Notice of Allowability	10/665,936	CHU ET AL.
	Examiner	Art Unit
	Sharan E Kannadu	1615
	Sharon E. Kennedy	1615
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to <u>amendment filed 12/14/2007 and subsequent telephone interview</u> .		
2. The allowed claim(s) is/are 74-76.		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No		
 Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). 		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	, 	
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	• •
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Dat 	
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🛛 Examiner's Amendn	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
of blological Matchai	9.	
•		

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Louis Cullman, Michelle Glasky and Janis Biksa on January 16, 2008.

The application has been amended as follows:

In the Claims:

Claims 77-83 have been cancelled.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance: Applicant amended the claims to require that the device be an aneurismal tissue treatment device, and included a Markush group of various therapeutic agents. The claims also require a pump and tubing. The closest prior art is now the patent to Urquhart, US 3,797,485, however, Urquhart does not disclose a pump for use with aneurysms, but for systemic administration of drugs through "intact blood vessels" (column 1, line 38) to avoid puncturing the blood vessel. Various drugs are administered. There is no suggestion absent hindsight reconstruction to use the Urquhart device for an aneurysm

Application/Control Number:

10/665,936

Art Unit: 1615

Page 3

in view that it is for intact tissue, and aneurysmal tissue is damaged and unpredictable,

and the device is for systemic delivery.

Any comments considered necessary by applicant must be submitted no later

than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

Contact Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Sharon E. Kennedy whose telephone number is

571/272-4948. The examiner can normally be reached on Monday-Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Michael Woodward, can be reached on 571/272-8373.

/Sharon E. Kennedy/

Sharon E. Kennedy
Primary Examiner

Art Unit 1615